AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ribonuclease 7

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9H1E1

UPID:

RNAS7_HUMAN

Alternative names:

Skin-derived antimicrobial protein 2

Alternative UPACC:

Q9H1E1; P80927; P83685; Q546N3

Background:

Ribonuclease 7, also known as Skin-derived antimicrobial protein 2, is a crucial protein exhibiting potent RNase activity. It plays a significant role in the body's defense mechanism, showcasing broad-spectrum antimicrobial activity against pathogens including uropathogenic E.coli and vancomycin-resistant Enterococcus faecium. Its bactericidal function, remarkably effective at low concentrations, operates independently of its RNase activity, primarily through compromising bacterial membrane integrity.

Therapeutic significance:

Understanding the role of Ribonuclease 7 could open doors to potential therapeutic strategies. Its potent antimicrobial properties and ability to maintain urinary tract sterility highlight its potential as a target for developing new antimicrobial agents, especially in the era of increasing antibiotic resistance.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.